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S U M M A R Y
Objective: Clinical treatment for blaKPC-positive Klebsiella pneumoniae isolates is challenging because the
recommended antibiotic options are limited and are extraordinarily expensive. This study aimed to
explore a new therapy for infection caused by KPC-producing K. pneumoniae.
Methods: Patients with blaKPC-positive K. pneumoniae infection, were prospectively screened and were
categorised into two groups: patients in the study group received a combination-based therapy of
cefepime and amoxicillin/clavulanic acid and the control group received tigecycline-based therapy. The
pathogen clearance rate, 28-day mortality and cost of the antibiotic treatment were compared between
the two groups. Moreover, the checkerboard microdilution method was performed to determine the
synergy between cefepime and amoxicillin/clavulanic acid in vitro.
Results: Twenty-six and 25 cases were enrolled in the study and control groups. The mortality and the
overall pathogen clearance rate showed no signiﬁcant differences (P=0.311 and P=0.447). Both the total
cost and the portion of the cost not covered by insurance were higher for the control group compared to
the study group (both P<0.001). Consistently, synergy (65.4%) and partial synergy (26.9%) were the main
effects.
Conclusions: In contrast to the currently recommended tigecycline-based therapy, cefepime and
amoxicillin/clavulanic acid combination was an effective and economical option to KPC-KP infection in
China.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Carbapenem-resistant Klebsiella pneumoniae (CRKP) has been a
major global health concern, as increasing CRKP infections have
been reported, especially in the past 20 years.1 Many carbapene-
mases are associated with carbapenem resistance in K. pneumo-
niae, such as K. pneumoniae-producing carbapenemase (KPC),
metal-b lactamases (IMP, VIM and NDM-1) and OXA-48 carba-
penemase.2–5 Of these, KPC, a plasmid-mediated serine-carbape-
nemase, is still the most common carbapenemase encountered in
K. pneumoniae. Of note, KPC-producing CRKP pathogens spread in a
clonal fashion, disseminating from the eastern United States to
Greece and from Zhejiang province to Taiwan, China.6,7
KPC-producing K. pneumoniae isolates are often associated with
severe healthcare-associated infection with high mortality ranging* Corresponding author. Tel./Fax: +86-571-86006142.
E-mail address: yvys119@163.com (Y. Yu).
http://dx.doi.org/10.1016/j.ijid.2015.07.024
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).from 43% to 53%, particularly among patients with bloodstream
infections. Thus, the treatment for KPC-producing K. pneumoniae
(KPC-KP) infection has been a major challenge because the
recommended antibiotic options are limited and extraordinarily
expensive.6 Therefore, many studies have made clinical attempts
to explore new treatment options for KPC-KP.8,9
Therapy based on tigecycline, colistin E or fosfomycin has
shown therapeutic beneﬁts against KPC-KP.10,11 Although tigecy-
cline has demonstrated an excellent spectrum of activity in vitro
against KPC-producing organisms, it is expensive and is often
associated with high mortality when applied as a monotherapy.12
Many experts suggest that a combination treatment based on
tigecycline could be a recommended choice for KPC-KP isolate
induced infection. This treatment program has been widely used in
other countries; however, it is not so widely applied in China
because it is expensive and not covered by medical insurance.
Besides, a treatment option based on colistin is unavailable in our
country because it is still not approved for sale in Mainland China.
Therefore, it is high time to explore feasible antibiotic options tociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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province is an area that has been worst hit by KPC-KP.13
Our previous study has showed that b-lactamase inhibitors,
especially clavulanic acid, demonstrated afﬁnity for the KPC-2
enzyme and inhibitory activity toward KPC producers.13Moreover,
a synergistic effect of cefepime and clavulanic acid against KPC-KP
in vitro was also illustrated. Thus, a prospective study was
designed to compare the clinical effects of cefepime in combina-
tion with amoxicillin/clavulanic with the currently recommended,
tigecycline-based combination therapy for KPC-producing K.
pneumoniae.
2. Patients and methods
2.1. Deﬁnitions
Healthcare-associated infection (HAI) was deﬁned as an
infection that occurred after exposure to hospitals or clinical
facilities and that usually be evident within 48 hours or longer
after admission. Deﬁnitive therapy was normally identiﬁed as
continuous antibiotic treatment over 48 hours. Clinical efﬁcacy of
the treatment was assessed at the sixth day of the deﬁnitive
therapy. The 28-day mortality rate was calculated from the ﬁrst
day of the targeted deﬁnitive therapy when KPC-producing K.
pneumoniae were identiﬁed. Pathogen clearance was deﬁned as at
least three continuous negative cultures, or the inability to obtain
specimens within two weeks.
2.2. Study design
All patients with conﬁrmed blaKPC-positive K. pneumoniae
infection, as shown by PCR ampliﬁcation, from a tertiary hospital in
east China between March 2011 and December 2012 were
prospectively screened to be involved in the study. The enrolled
patients were randomly divided into two groups according to
different deﬁnitive treatment options: the study group received
normal doses of cefepime (1g q6hd-1) in combination with
amoxicillin/clavulanic acid (1.2g q6hd-1), and the control group
received the currently recommended tigecycline-based treatment
(loading dose, 100 mg, decreased to 50mg q12hd-1). The speciﬁc
infection types included pneumonia, intra-abdominal infection
bloodstream infection, and urinary tract infection. Fosfomycin was
included in the treatment of some patients of the study group, and
the treatment was subdivided into two subgroups. While in the
tigecycline group, six different combination programs were
analysed, including tigecycline alone, tigecycline in combination
with fosfomycin, tigecycline with amikacin and levoﬂoxacin,
tigecycline with cefepime, tigecycline with cefoperazone/sulbac-
tam, or tigecycline with meropenem (Table 2).
The institutional review board of Sir Run Run Shaw Hospital
approved the study protocol. Written informed consents were
obtained from all patients or from their legally representatives.
2.3. Pathogen identiﬁcation and MIC detection
The isolates were ﬁrst identiﬁed using the VITEK compact
2 system (AB bioMe´rieux, France), and the minimum inhibitory
concentrations (MICs) of 13 antibiotics were determined by the
Etest method (AB bioMe´rieux, France), which included ceftriaxone,
cefepime, amoxicillin/clavulanic acid, piperacillin/tazobactam,
cefoperazone/sulbactam, aztreonam, imipenem, meropenem, ami-
kacin, levoﬂoxacin, fosfomycin, colistin and tigecycline. Suscepti-
bility to a drug was interpreted according to the CLSI guideline
(2013).14 The resistance breakpoints of cefepime and amoxicillin/
clavulanic acid were 32 mg/L and 32/16 mg/L, respectively. Due
to the absence of CLSI criteria, FDA and EUCAST guidelines wereused as references to interpret the resistant tigecycline (8 mg/L)
and colistin (>2 mg/L) results, respectively.15,16
2.4. Data collection
For all enrolled patients, the following data were collected: age,
sex, prior ICU admission, comorbidities, risk factors, source of
bacteraemia, mixed infectious pathogens, hospital length of stay,
duration of antibiotic therapy and Acute Physiologic and Chronic
Health Evaluation (APACHE) II scores. The APACHE II scores were
based on the data collected at admission that were to be involved
in our study during the ﬁrst 24 hours.
2.5. Statistical analysis
Descriptive data were reported as the means SD, median
(interquartile range) or number and percentage. With respect to the
differences in the 28-day mortality rates, pathogen clearance rates
and cost of the antibiotic treatment between the two groups,
categorical variables were compared using chi-square analysis.
Continuous variables were compared using an independent Sample
T test for normally distributed data, and the Mann-Whitney U test
was used for non-normally distributed data. Statistical analysis was
performed using SPSS 19.0 (Chicago, Ill, USA), and statistical
signiﬁcance was deﬁned as P <0.05.
2.6. Combination effect of cefepime combined with amoxicillin/
clavulanic acid in vitro
The checkerboard microdilution method was used to determine
the in vitro activity of cefepime combined with amoxicillin/
clavulanic acid.17 The active components ratio of amoxicillin and
clavulanic acid was 1:5 (amoxicillin vs clavulanic acid). The
fractional inhibitory concentration (FIC) and FIC index (FICI) were
calculated for each combination, and interpretation of the FICI was
as follows: 0.5, synergy; >0.5 to <1, partial synergy; 1, additive;
>1 to <4, indifference; and 4, antagonism.
3. Results
All CRE isolates collected between March 2011 and December
2012 in our hospital were included in advance, and were submitted
to sequencing of the blaKPC gene. Sixty-two patients were primarily
screened and randomly divided into the study and control groups
after nucleotide sequencing. Fifty-one patients were enrolled in
the study. Of these patients, 26 received the cefepime combined
with amoxicillin/clavulanic acid therapy, while 25 received the
tigecycline-based treatment (Fig. 1).
Patients’ symptoms and inﬂammation index, and each patient
with at least twice positive culture results, supported that all
blaKPC-positive K. pneumoniae isolates were the real pathogens
associated with infections. Thirteen patients (8+5) whose patho-
gens were isolated from sputum met the diagnosis criteria of
Hospital Associated Pneumonia (HAP) by CT scan or X-ray results
(Table 1). There were no signiﬁcant differences in the baseline
characteristics between the two groups, except that more patients
in the tigecycline group had a history of surgery (88% vs 57.7%,
P=0.046) (Table 1).
3.1. MIC distribution
Most isolates presented typical features of KPC-KP pathogens,
being highly resistant to both carbapenems and broad-spectrum
cephalosporins, except for colistin and tigecycline. The MICs of
tigecycline were distributed from 0.25 to 1 mg/L in all isolates.
Figure 1. Study proﬁle.
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cefepime combined with amoxicillin/clavulanic acid and tigecycline
The overall 28-day mortality rate was 29.0%, and the mortality of
the study group was lower than that of the tigecycline group (23.1%
vs 36.0%, respectively), although this difference was not signiﬁcant
(P=0.311). The pathogen clearance rate was 62.7% (32/51), with
57.7% (15/26) and 68.0% (17/25) for two groups, respectively
(P=0.447) (Table 2). When compared to the tigecycline mono-
therapy, the cefepime and amoxicillin/clavulanic acid treatment
tended to have lower mortality (20.8% vs 60%, P=0.075) and a similar
pathogen clearance rate (53.8% vs 60.0%, P=0.945).
3.3. Susceptibility results and in vitro activity of cefepime in
combination with amoxicillin/clavulanic acid
The KPC-producing isolates appeared to present higher MIC
values to both amoxicillin/clavulanic acid and cefepime. The MIC
ranges of cefepime and amoxicillin/clavulanic acid in the 26 tested
isolates were 14096 mg/L and 644096 mg/L, respectively, whenthey were used alone (Supplementary Table 1). Furthermore, the
checkerboard results indicated that the MIC of cefepime was
dramatically decreased when amoxicillin/clavulanic acid was
combined. Consistently, synergy was the main effect in 65.4%
patients, followed by partial synergy (26.9%) and then indifference
(7.7%). Of note, antagonism was not found in any of the tests
(Fig. 2). The MIC of cefepime was drastically reduced 232 times
after combination, and the MIC of amoxicillin/clavulanic acid was
even reduced 2256 times. The combination treatment was
signiﬁcantly different from both the cefepime and amoxicillin/
clavulanic acid treatment alone (P =0.013 and <0.001, respective-
ly), which implies a powerful combinatorial effect between
cefepime and amoxicillin/ clavulanic acid (Supplementary
Table 1).
3.4. Antibiotic cost for KPC-KP treatment
As shown in Table 3, the total antibiotic cost was extremely
higher for the tigecycline group ($3465 vs $1109, P<0.001)
compared to that of the study group. Given that tigecycline is
Table 1
Patient Baseline Demographics Treated with Cefepime in combination with
Amoxicillin/ Clavulanic Acid Group vs Tigecycline Group








Age, y, 67.1 16.1 63.617.8 0.457
Sex, Male, n (%) 18 (69.2%) 13 (52%) 0.208
Prior ICU admission, n (%) 19(73%) 18 (72.0%) 0.931
Comorbidities, n (%)
Diabetes mellitus 4 (15.4%) 1 (4.0%) 0.172
Congestive heart disease 13 (50.0%) 8 (32.0%) 0.049
Chronic obstructive
pulmonary disease
2 (7.7%) 4 (16.0%) 0.246
Chronic liver disease 1 (3.8%) 3 (12.0%) 0.26
Cholelithiasis 6 (23.1%) 3(12.0%) 0.269
Hematological
malignancies
1 (3.8%) 0 (0%) 0.322
Risk factors, n (%)
Surgery 15 (57.7%) 22 (88.0%) 0.046
Central venous catheter 15 (57.7%) 24 (96.0%) 0.564
Mechanical ventilation 12 (46.2%) 16 (64.0%) 0.2
Urinary catheter 6 (23.1%) 6 (24.0%) 0.251
Carbapenem Exposures 22 (84.6%) 21 (84.0%) 0.952
Hemodialysis 1(3.8%) 2(8.0%) 0.529
Source of bacteria, n (%)
Sputum 8 (31%) 5 (20%) 0.177
Peritoneal ﬂuid 3 (12%) 10 (40%)
Blood 4 (15%) 2 (8%)
Urine 1 (4%) 0
Cerebrospinal ﬂuid 0 1 (4%)
Two or more sources 10 (38%) 7 (28%)
Mixed infectious pathogens
A. baumannii 1 (4%) 5 (20%) 0.337
E. coli 1 (4%) 1 (4%)
E. faecalis 1 (4%) 1 (4%)
S. maltophila 0 1 (4%)
Median length of hospital
stay, days
9.0(4.8-15.5) 9.0 (6.5-14.5) 0.397
APACHE II scores 16.08.8 17.19.3 0.683
Mean duration of antibiotic
therapy, day
10.37.2 10.65.5 0.339
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other antibiotics used in this study, including cefepime and
amoxicillin/clavulanic acid, the difference in total antibiotic cost
that was not covered by insurance (paid by patients) between the
two groups was signiﬁcantly different ($3221 vs $222, P<0.001).
4. Discussion
In this study, we treated two groups of patients infected by KPC-
KP, and the overall 28-day mortality was 29.0%. The mortality of
the study group (cefepime combined with amoxicillin/clavulanicTable 2
Mortality and pathogen clearance of patients treated with cefepime combined with am
Deﬁnitive treatment M
Cefepime + Amoxicillin/ clavulanic acid based antimicrobial therapy# 6
Cefepime + Amoxicillin/clavulanic acidy 5
Cefepime + Amoxicillin/clavulanic acid + fosfomycin 1
Tigecycline based antimicrobial therapy## 9
Tigecycline monotherapyyy 3







P a, # group vs ## group; P b, y group vs yy group.acid group) was tended to be lower than that of the control group
(tigecycline-based treatment group) (23.1% vs 36.0%, P=0.311). The
pathogen clearance rate was 57.7% and 68.0% for the two groups,
respectively (P=0.447). With respect to the ﬁnancial burden, both
the total antibiotic cost and the portion not covered by medical
insurance were by far higher for the tigecycline-based treatment
group compared to the study group ($3465 vs $1109, and $3221 vs
$222; both P<0.001). Moreover, synergy (65.4%) and partial
synergy (26.9%) were the main effects when cefepime was
combined with amoxicillin/clavulanic acid in the checkerboard
microdilution test. Therefore, compared to the currently recom-
mended tigecycline-based therapy, cefepime and amoxicillin/
clavulanic acid combination therapy was an effective and
economical option to control KPC-producing K. pneumoniae
infection.
KPC-producing K. pneumoniae shows wide hydrolytic activity
toward multiple classes of antibiotics, such as carbapenems,
cephalosporins, penicillins and the monobactam aztreonam,
rendering them ineffective. This organism is also associated with
severe infections with high mortality. Unfortunately, the optimal
antimicrobial therapy for KPC-KP infection is not well established,
and the clinical outcome data remains sparse.1 Of note, our
previous study has demonstrated that KPC-KP isolates have widely
spread around China and have become a particularly worrisome
problem due to the location of its plasmid.7,13 However, clinical
and efﬁcacy data for KPC-KP infection treatment are still lacking.
Therefore, it is very necessary to explore effective therapy options
to control infection caused by KPC-KP.
Although KPC-KP isolates are non-susceptible to carbapenems
in most cases, some researchers have still argued that carbape-
nems could be used as treatment against KPC-KP by prolonging the
infusion time or increasing the drug dose, especially in conditions
of intermediate MICs (meropenem MICs of 4 mg/L).18 In fact,
supported by a series of retrospective analyses and in vitro synergy
susceptibility tests, some researchers have claimed that clinical
efﬁcacy and outcome are highly dependent on the MIC levels of
carbapenems.18 Carbapenem regimens were inapplicable as
deﬁnitive treatment options in our study because most of our
KPC-KP isolates showed high MIC levels to these antibiotics (over
32 mg/L).7 Therefore, anti-infectious treatment based on several
other antibiotics, such as colistin, tigecycline and fosfomycin, have
been widely applied. However, these regimens are always
relatively limited in their clinical application, especially when
administered as a monotherapy. For example, a series of
systematic reviews and clinical trials have emphasised that
tigecycline monotherapy is pooled with safety and efﬁcacy, and
clinicians should avoid tigecycline monotherapy for the treatment
of severe infection.19,20 According to a previous report, the most
common successful combination regimens used in KPC-KP
bacteraemia were either colistin-polymyxin B or tigecycline inoxicillin/ clavulanic acid and tigecycline
ortality, n (%) Pathogen clearance, n (%) Total, n
(23.1%) 15 (57.7%) 26
 (20.8%) 14(58.8%) 24 (92.3%)
 (50%) 1(50.0%) 2 (7.7%)
 (36.0%) 17(68.0%) 25
 (60%) 3(60.0%) 5 (20%)
 (25%) 9(75.0%) 12 (48%)
 (33.3%) 3(100.0%) 3 (25%)
 (50%) 1(50.0%) 2 (8%)
 (100%) 0 (0%) 1 (4%)
 (0%) 1(100.0%) 1 (4%)
.311 0.447
.075 0.945
Figure 2. In vitro activity of cefepime in combination with amoxicillin/ clavulanic acid.
Table 3
Antibiotic cost for KPC-producing K. pneumoniae infection






Total antibiotic cost 1109  767 3465  2082 <0.001
Antibiotic cost per day 108  5 321  34 <0.001
Total antibiotic cost not covered by insurance 222  153 3221  1540 <0.001
Antibiotic cost not covered by insurance per day 22  1 302  7 <0.001
S. Ji et al. / International Journal of Infectious Diseases 38 (2015) 108–114112combination with a carbapenem regimen.1 It has been conﬁrmed
that combined therapies with two or more drugs in vivo are
beneﬁcial for improving survival rate and for avoiding pathogen
resistance. Recent studies have revealed that the polymyxins
[polymyxin B and polymyxin E (colistin)] have low success rate
when used alone, but they exhibit higher activity when used in
combination.21,22 The most frequently utilised combinations
include tigecycline with colistin, colistin with aminoglycosides
or tigecycline/colistin with fosfomycin. Unfortunately, polymyxins
are still unavailable in Mainland China, while tigecycline is not
included in the National Health Insurance price listing, which have
made the choice of antibiotics for KPC-KP infection in China very
limited.
Cefepime is a semi-synthetic, broad-spectrum, fourth-genera-
tion cephalosporin that has been widely used since its approval for
clinical use in 1997.23 It is currently recommended in several
guidelines for the empirical treatment of febrile neutropenia, severe
community-acquired pneumonia, and late-onset hospital-acquiredpneumonia.23 With increasing application, more clinical trials have
found increased mortality in patients receiving cefepime therapy,
but the combination of this antibiotic with other antibiotic agents
might be an effective way to improve its efﬁcacy.24 Cardile et al. also
reported a successful treatment case where using high doses of
cefepime and levoﬂoxacin to treat KPC-expressing Enterobacter
cleacae empyema showed an intermediate effect to that of cefepime
and levoﬂoxacin (MIC=16 mg/L).25
Clavulanic acid is an irreversible ‘suicide’ inhibitor of intracel-
lular and extracellular b-lactamases that is effective against a wide
variety of these enzymes and protects amoxicillin from inactiva-
tion by many b-lactamases. As a consequence, studies on the
antibacterial activity of amoxicillin/clavulanic acid have been
restored at a time when the spread of resistance due to b-
lactamase production severely threatens its usefulness. However,
little evidence is available regarding the clinical efﬁcacy of
clavulanic acid toward KPC carbapenemases. Our previous study
found that cefepime in combination with amoxicillin/clavulanic
S. Ji et al. / International Journal of Infectious Diseases 38 (2015) 108–114 113acid is effective toward KPC-KP isolates (data not shown). Supported
by evidence from the checkerboard microdilution method, we aim to
use the combination therapy to treat patients infected by KPC-KP.
The checkerboard microdilution test showed a signiﬁcant synergis-
tic effect for amoxicillin/clavulanic acid and cefepime, therefore, it
seems that clavulanic acid has a higher hydrolytic activity than KPC
carbapenems in vitro, which is different from results of previous
studies. We further evaluated the clinical efﬁcacies of these drugs by
comparing the 28-day mortality and pathogen clearance of patients
treated with these drugs to those treated with tigecycline. Because
many reports have proven the effectiveness of tigecycline in
controlling KPC-KP infection, treatment options based on tigecycline
were utilised as a control in this study.
In our study, most patients in the control group had received
multiple antibiotics before tigecycline was used. The higher
mortality of tigecycline monotherapy (60%) also supported that
combination programs would be more effective and safe in the
control group (Table 2). Therefore, a combination program —
tigecycline combined with at least one drug to which the isolate
was susceptible, was utilized in our study.
As shown in our study, the pathogen clearance rate was 62.7%
(32/51), with 57.7% (15/26) and 68.0% (17/25) for two groups,
respectively (P=0.447), which suggested that the cefepime
combined with amoxicillin/clavulanic acid treatment might be a
superior treatment option when compared with tigecycline-based
treatment in regard to clinical safety and efﬁcacy (Table 2).
However, relatively lower microbiological clearance was observed
in the study group compared to the control group (57.7% vs 68%),
which indicated that the cefepime combined with amoxicillin/
clavulanic acid treatment might be inferior to the tigecycline
treatment in microbiological eradication. Furthermore, cefepime
in combination with amoxicillin/clavulanic acid presented signiﬁ-
cantly fewer medical expenses compared to the tigecycline-based
group when used against the blaKPC-positive K. pneumoniae
isolates. These results suggested that the combination therapy
option is an appropriate consideration for treating patients
infected with KPC-KP.
Although its in vitro activity among many pathogens is
promising, tigecycline is not recommended for the treatment of
bloodstream, central nervous system or urinary tract infections
due to its low concentrations in serum, cerebrospinal ﬂuid and
urine, and an increased in the MIC of tigecycline against a pathogen
is often observed during monotherapy.26 Moreover, the mortality
rate of the cefepime and amoxicillin/clavulanic acid group found in
our study was 23.1%, which was lower than the rates reported for
KPC-KP bacteraemia in previous studies.1
In China, medical insurance covers most citizens, and over 70%
of medical expanses can be reimbursed. Some new antimicrobials,
e.g. tigecycline, are excluded from the insurance policy, and
patients currently have to pay the full price for these drugs. In
contrast, approximately 80% of the cost of cefepime and
amoxicillin/clavulanic acid covered in our country. Based on the
situation in China, our results conﬁrmed the expenses of the study
group were signiﬁcantly lower than the tigecycline group
(P<0.001), which indicated that the cefepime combined with
amoxicillin/clavulanic acid treatment was a more suitable
treatment option due to Chinese policy.
4.1. Limitations of the study
Our study has several limitations. First, as a prospective study,
the number of cases in the study is relatively small, and more
meaningful results could be obtained if more patients were
involved. Second, if the combinatorial effect of cefepime with
amoxicillin/clavulanic acid could be detected before the treatment,
then our treatment would be more purposeful.In conclusion, our study explores the clinical treatment efﬁcacy
of amoxicillin/clavulanic acid in combination with cefepime
toward KPC-positive K. pneumoniae isolates. By comparing the
results with those of a group treated with tigecycline, we found
that patients who received amoxicillin/clavulanic acid with
cefepime treatment showed no difference in clinical efﬁcacy.
Therefore, we suggest that amoxicillin/clavulanic acid in combi-
nation with cefepime could be recommended as a treatment choice
in special situations, such as when no drugs are available or for
infection of special sites (e.g. CNS, bloodstream or urinary tract).
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